cancer research

Researchers led by Dr. Jona Kayser at MPZPM report that physical processes in dense cell populations play a decisive role in determining the optimal timing of treatment cycles. The finding addresses treatment resistance, described as one of the key challenges in cancer and antibiotic therapy, and suggests treatment scheduling could be improved by accounting for how densely packed cells interact physically rather than relying on biological factors alone.

A new study shows that loss of parts of the Y chromosome, a change seen in many men as they age, can actively drive cancer development. Researchers report the missing genetic material affects tumour growth in men, offering a possible explanation for why certain cancers behave differently between the sexes.

UF Health researchers report that cancer diagnoses in the United States drop sharply during holiday periods, while outcomes for patients diagnosed around those dates are worse. The findings suggest holiday disruptions delay screenings and follow-up care, allowing cancers to be caught at later, harder-to-treat stages, and raise questions about how seasonal healthcare patterns affect patient survival.

Researchers report that a 'proliferative pause' — a dormant phase some cancer cells enter before spreading to the brain — may offer a critical window to intervene and stop brain metastasis before it begins. The finding could shape new strategies for preventing one of the deadliest complications of cancer, and is drawing attention from oncology and precision medicine communities.

Researchers, including Italy's National Institute for Nuclear Physics, report that theoretical physics methods have helped reveal how extra-chromosomal DNA behaves inside tumour cells. These circular DNA fragments, separate from chromosomes, are known to drive cancer growth and drug resistance. Applying physics-based modelling to their molecular mechanisms offers new insight that could inform future cancer research and treatment strategies.

Researchers report that biological characteristics of prostate cancer tumours can help identify which patients are most likely to benefit from hormone therapy. The finding suggests tumour biology could be used to tailor treatment decisions rather than applying hormone therapy uniformly. Details of the study, including sample size and clinical impact, were not provided, but the work points toward more personalised prostate cancer care.

A Nature study reports that the p53 protein, best known as a tumour suppressor, prevents chromothripsis — the shattering of chromosomes — by keeping transcription and DNA replication in balance. When p53 is missing or inactive, these processes collide, causing catastrophic genome damage that can drive cancer development. The finding links a classic cancer gene to a new mechanism of genome protection, and researchers say it may refine how tumour evolution and genome instability are understood.